4D Molecular Therapeutics reports clinical, financial and governance developments for a late-stage biotechnology company developing disease-targeted gene therapy product candidates. Its recurring updates center on 4D-150 for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, and on clinical programs such as 4FRONT, PRISM and SPECTRA.
Company news also covers quarterly and annual financial results, cash runway commentary, collaboration and license revenue tied to Otsuka, investor conference participation, board and leadership changes, and employment inducement equity grants. The company states that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulatory authorities.
4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation at the Clinical Trials at the Summit (CTS) Meeting in Park City, Utah, on June 8, 2024. The company will present 24-week data from the Phase 2 Dose Expansion Stage of the PRISM Trial evaluating 4D-150 in wet AMD patients with severe disease activity. The presentations will cover topics including designing registration trials with the latest FDA guidance and challenges in bringing new treatment options to market. Key speakers include Robert Kim, M.D., Carl Danzig, M.D., and David Kirn, M.D.
4D Molecular Therapeutics (Nasdaq: FDMT), a leader in genetic medicines, has announced its participation in key investor conferences in June 2024. The company will be represented at the Jefferies Global Healthcare Conference on June 6 at 2:30 p.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 2:00 p.m. ET. These events will feature fireside chats and one-on-one meetings with the management team. Archived webcasts of these presentations will be available for up to a year on the 4DMT website for interested investors.
4D Molecular Therapeutics (Nasdaq: FDMT) will present interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for cystic fibrosis lung disease at the 47th European Cystic Fibrosis Conference on June 6, 2024. Dr. Jennifer L. Taylor-Cousar will present the data at 5:00 p.m. BST. The company will also host a webcast to discuss the data and provide a program update on the same day at 8:00 a.m. ET.
The presentation, titled 'CFTR transgene expression in airway epithelial cells following aerosolized administration of the AAV-based gene therapy 4D-710 to adults with cystic fibrosis lung disease,' will be part of the session 'Where are we with new therapeutic approaches?'
The webcast will be archived on the 4DMT website for one year.
4DMT reported positive interim data from the PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients, advancing into Phase 3 by Q1 2025. They presented 24-week analysis from the Population Extension cohort and Phase 1/2 AEROW trial at upcoming conferences. Additionally, they completed a public follow-on offering raising $337 million, ensuring cash runway into H1 2027.
4D Molecular Therapeutics, a leading genetic medicines company, will participate in an investor conference in May. The management team will conduct a fireside chat and be available for one-on-one meetings. The presentation will take place on May 14, 2024, at the Bank of America Health Care Conference.
4DMT, a genetic medicines company, announced presentations at the 2024 ARVO Annual Meeting, including interim results from the PRISM Phase 2 trial for 4D-150 and preclinical data on 4D-175. The Company aims to treat diseases like AMD through genetic medicine.
Summary not available.
Summary not available.
Summary not available.
Summary not available.